- Defining secondary progressive multiple sclerosis2016 | First Faculty of Medicine
- The risk of secondary progressive multiple sclerosis is geographically determined but modifiable2023 | First Faculty of Medicine
- Management of secondary-progressive multiple sclerosis2022 | Second Faculty of Medicine
- Approaches and challenges in the diagnosis and management of secondary progressive multiple sclerosis: A Central Eastern European perspective from healthcare professionals2021 | First Faculty of Medicine
- Risk of secondary progressive multiple sclerosis: A longitudinal study2020 | First Faculty of Medicine
- Siponimod in the treatment of secondary - progressive multiple sclerosis - case report2022 | Faculty of Medicine in Hradec Králové
- Proportion of alemtuzumab-treated patients converting from relapsing-remitting multiple sclerosis to secondary progressive multiple sclerosis over 6 years2020 | First Faculty of Medicine
- Disability accrual in primary and secondary progressive multiple sclerosis2023 | First Faculty of Medicine
- Long-term efficacy and safety of siponimod in patients with secondary progressive multiple sclerosis2022 | Faculty of Medicine in Hradec Králové
- Treatment patterns in secondary progressive multiple sclerosis a multi-country registry study from five European countriesPublication without faculty affiliation
- Long‑term effect of siponimod on MRI outcomes in patients with secondary‑progressive multiple sclerosis2022 | Faculty of Medicine in Hradec Králové
- Association of Sustained Immunotherapy With Disability Outcomes in Patients With Active Secondary Progressive Multiple Sclerosis2020 | First Faculty of Medicine
- Effects of High- and Low-Efficacy Therapy in Secondary Progressive Multiple Sclerosis2021 | First Faculty of Medicine
- Proportion and characteristics of secondary progressive multiple sclerosis in five European registries using objective classifiers2023 | First Faculty of Medicine
- Long--term efficacy and safety of siponimod in patients with secondary progressive multiple sclerosis: Analysis of EXPAND core and extension data2023 | Faculty of Medicine in Hradec Králové
- Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis2019 | First Faculty of Medicine
- Active secondary progressive multiple sclerosis treatment with a selective sphingosine-1-phosphate receptor modulator2020 | First Faculty of Medicine
- Siponimod for the treatment of adult patients with secondary progressive multiple sclerosis - current experience2021 | Faculty of Medicine in Hradec Králové
- Autologous haematopoietic stem cell transplantation for secondary progressive multiple sclerosis: an exploratory cost-effectiveness analysis2010 | Third Faculty of Medicine
- The Benefits and Risks of Switching from Fingolimod to Siponimod for the Treatment of Relapsing-Remitting and Secondary Progressive Multiple Sclerosis2023 | First Faculty of Medicine, Faculty of Medicine in Hradec Králové, Second Faculty of Medicine
- Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension2018 | First Faculty of Medicine
- Research Report University Hospital clinical trial 101MS326Publication without faculty affiliation
- Siponimod in the treatment of multiple sclerosis - a case study2022 | Faculty of Medicine in Hradec Králové
- Ofatumumab and siponimod in the treatment of multiple sclerosis - case reports2022 | Faculty of Medicine in Hradec Králové
- Siponimod2020 | First Faculty of Medicine
- Heterogeneity on long-term disability trajectories in patients with secondary progressive MS: a latent class analysis from Big MS Data network2023 | First Faculty of Medicine
- Anti-inflammatory disease-modifying treatment and short-term disability progression in SPMS2017 | First Faculty of Medicine